FDA Brief

Warning letters Food

FDA warning letter to

Flax & More Corporation

High riskIssued May 12Posted Jun 30Human Foods Program

FDA warned Flax & More Corporation that its dietary supplements were made under conditions that failed required manufacturing quality rules.

What happened

FDA inspected the facility from October 21 through 29, 2025, and issued a Form FDA 483 listing inspection observations at the close. The inspection found violations of current good manufacturing practice (CGMP), the required quality rules for dietary supplement manufacturing; FDA calls the products adulterated, meaning they were prepared under conditions that do not meet CGMP requirements. FDA found dietary supplement residue in equipment seams and missing or incomplete product specifications and master manufacturing records, and it found the firm’s November 20, 2025 response insufficient.

What FDA found

  1. FDA found that equipment seams were not maintained to prevent residue buildup; a hopper had dietary supplement residue in its seams, and shared equipment was used for products with and without wheat bran.

    21 CFR 111.27(a)(4)
  2. The firm did not establish finished-product specifications for identity, purity, strength, and composition of its dietary supplements.

    21 CFR 111.70(e)
  3. The master manufacturing record for a product lacked a theoretical yield statement, including maximum and minimum yield limits for deviation review, and lacked sampling procedures or a cross-reference to test procedures.

    21 CFR 111.210(f); 21 CFR 111.210(h)(2)

What FDA wants

FDA asks the firm to notify it in writing within 15 working days of receipt of the letter of specific steps taken to address the violations, with explanations, documentation, and steps to prevent recurrence. If corrective actions cannot be completed in that time, the firm must state why and when it will finish.

Who should pay attention

  • dietary supplement brands that use contract manufacturers
  • companies making allergen-free products on shared equipment
  • quality teams responsible for cleaning and manufacturing records

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk